GRI Bio, Inc. (GRI)

USD 0.75

(-4.1%)

Market Cap (In USD)

6.68 Million

Revenue (In USD)

21.76 Million

Net Income (In USD)

-13.03 Million

Avg. Volume

683.08 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.302-65.0
PE
-
EPS
-
Beta Value
-1.7958997
ISIN
US3622AW2059
CUSIP
-
CIK
84112
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Albert Agro Ph.d.
Employee Count
-
Website
https://www.gribio.com
Ipo Date
2021-02-10
Details
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.